A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

Last updated:
2026-08-15
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, PLACEBO-CONTROLLED, PARTICIPANT- AND INVESTIGATOR-BLINDED STUDY TO EVALUATE THE EFFICACY IN REDUCING ATRIAL FIBRILLATION BURDEN (AFB) AS WELL AS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL PKN605 IN PARTICIPANTS WITH ATRIAL FIBRILLATION

Intervention/treatment:
PKN605
Medical condition:
ATRIAL FIBRILLATION
Protocol code:
CPKN605A12201
Control number:
298720
Status:
Recruiting
Approved:
July 03, 2025
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT07217067
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Novartis Pharmaceuticals
Role
CONTACT
Phone:
1-888-669-6682
Name
Novartis Pharmaceuticals
Role
CONTACT
Phone:
+41613241111
Sponsor
NOVARTIS PHARMACEUTICALS CANADA INC

Locations

Alberta

Novartis Investigative Site
Calgary, Alberta, T2P 3C5
Recruiting

British Columbia

Novartis Investigative Site
Vancouver, British Columbia, V5Z 1M9
Recruiting

Nova Scotia

Novartis Investigative Site
Halifax, Nova Scotia, B3H 3A7
Recruiting

Ontario

Novartis Investigative Site
Hamilton, Ontario, L8L 2X2
Recruiting
Novartis Investigative Site
London, Ontario, N6A 5W9
Recruiting
Novartis Investigative Site
Newmarket, Ontario, L3Y 2P6
Recruiting
Novartis Investigative Site
Toronto, Ontario, M4N 3M5
Recruiting
Novartis Investigative Site
Toronto, Ontario, M5B 1W8
Recruiting

Quebec

Novartis Investigative Site
Montreal, Quebec, H1T 1C8
Recruiting
Novartis Investigative Site
Montreal, Quebec, H2X 1R9
Recruiting
Novartis Investigative Site
Montreal, Quebec, H4A 3J1
Recruiting
Novartis Investigative Site
Québec, Quebec, G1V 4G5
Recruiting
Novartis Investigative Site
Sherbrooke, Quebec, J1H 5N4
Recruiting
Did you find what you were looking for?